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Abstract
The multiligand Receptor for Advanced Glycation End products (RAGE) is involved in various pathophysiological processes,
including diabetic inflammatory conditions and Alzheimer`s disease. Full-length RAGE, a cell surface-located type I
membrane protein, can proteolytically be converted by metalloproteinases ADAM10 and MMP9 into a soluble RAGE form.
Moreover, administration of recombinant soluble RAGE suppresses activation of cell surface-located RAGE by trapping RAGE
ligands. Therefore stimulation of RAGE shedding might have a therapeutic value regarding inflammatory diseases. We
aimed to investigate whether RAGE shedding is inducible via ligand-induced activation of G protein-coupled receptors
(GPCRs). We chose three different GPCRs coupled to distinct signaling cascades: the V2 vasopressin receptor (V2R) activating
adenylyl cyclase, the oxytocin receptor (OTR) linked to phospholipase Cb, and the PACAP receptor (subtype PAC1) coupled
to adenylyl cyclase, phospholipase Cb, calcium signaling and MAP kinases. We generated HEK cell lines stably coexpressing
an individual GPCR and full-length RAGE and then investigated GPCR ligand-induced activation of RAGE shedding. We
found metalloproteinase-mediated RAGE shedding on the cell surface to be inducible via ligand-specific activation of all
analyzed GPCRs. By using specific inhibitors we have identified Ca2+ signaling, PKCa/PKCbI, CaMKII, PI3 kinases and MAP
kinases to be involved in PAC1 receptor-induced RAGE shedding. We detected an induction of calcium signaling in all our
cell lines coexpressing RAGE and different GPCRs after agonist treatment. However, we did not disclose a contribution of
adenylyl cyclase in RAGE shedding induction. Furthermore, by using a selective metalloproteinase inhibitor and siRNA-
mediated knock-down approaches, we show that ADAM10 and/or MMP9 are playing important roles in constitutive and
PACAP-induced RAGE shedding. We also found that treatment of mice with PACAP increases the amount of soluble RAGE in
the mouse lung. Our findings suggest that pharmacological stimulation of RAGE shedding might open alternative treatment
strategies for Alzheimers disease and diabetes-induced inflammation.
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Introduction
The Receptor for Advanced Glycation End products (RAGE) is
a type I transmembrane protein belonging to the immunoglobulin
superfamily and is usually expressed at low levels in epithelial,
neuronal and vascular cells. The lung is the sole organ having high
expression of RAGE under normal conditions [1].
RAGE has been shown to play a crucial role in chronic
inflammatory diseases, late diabetic complications, atherosclerosis
and Alzheimers disease [2]. Proteins and peptides such as
advanced glycation end products (AGEs), Ab peptides, S100/
calgranulin family members and HMGB1 (amphoterin, high-
mobility group protein B1) have been identified as ligands for
RAGE [3]. Ligand binding of RAGE induces production of
proinflammatory cytokines from macrophages [4], [5] and
amplifies inflammatory responses [6]. Moreover, the expression
of RAGE is induced by an autocrine mechanism upon the binding
of RAGE ligands [7]. The concentration of AGEs is enhanced
under some pathological circumstances such as diabetes mellitus,
inflammation, oxidative stress, renal failure [8] and Alzheimers
disease [9]. Therefore, in these pathological conditions the ligand-
induced increase of full-length RAGE expression contributes to
the severity of these diseases.
Numerous studies have shown that administration of soluble
RAGE (sRAGE) can alleviate full-length RAGE-mediated harmful
processes by trapping RAGE ligands and preventing RAGE
signaling. For example the application of sRAGE slowed-down
tumor growth and reduced the amount of metastases in mice [10].
Other studies demonstrate that treatment with sRAGE can
completely suppress diabetic atherosclerosis [11] and reverse
vascular hyperpermeability in diabetic rats [12]. Injection of
soluble RAGE into the brain of an Alzheimers disease mouse
model reduced the levels of Ab, Ab plaques and BACE1 (beta-site
APP Cleaving Enzyme 1) [13]. We as well as others have shown
that full-length RAGE is subjected to protein ectodomain shedding
conducted by metalloproteinase ADAM10 [14], [15], [16].
ADAM10 (A Disintegrin And Metalloproteinase 10) is a multido-
main type I transmembrane zinc-dependent metalloproteinase
[17]. Shedding processes are known to be inducible by calcium
ionophores and phorbol esters. Moreover a-secretase-mediated
shedding of the amyloid precursor protein (APP) is achievable by
ligand-induced activation of G protein-coupled receptors (GPCRs)
[18], [19], [20].
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As soluble RAGE alleviates pathophysiological processes
mediated by full-length RAGE, the stimulation of RAGE shedding
may be used as a therapeutic attempt in the treatment of diseases
such as Alzheimer and diabetes mellitus. The aim of our study was
to investigate whether full-length RAGE is proteolytically con-
verted into soluble RAGE following activation of G protein-
coupled receptors (GPCRs). To answer this question, we in-
vestigated GPCRs stimulating various main signaling networks:
the V2 vasopressin coupled to adenlylyl cyclase [21], the oxytocin
receptor linked to phospholipase Cb [22] and the PAC1 (pituitary
adenylate cyclase-activating polypeptide) receptor known to be
able to activate adenylyl cyclase, phospholipase Cb, calcium
signaling and MAP (mitogen-activated protein) kinases [23].
The neuropeptide PACAP exhibits anti-inflammatory and
neuroprotective properties primarily mediated through the
PAC1 receptor [23]. Moreover, in previous studies we demon-
strated that activation of the PAC1 receptor induces a-secretase
ADAM10-mediated APP cleavage in cultured cells [19] and in vivo
[24]. Thus, the PACAP/PAC1 system provides an ideal model to
investigate signaling pathways involved in metalloproteinase-
induced RAGE shedding. Since PACAP receptors are also present
in the lung, being the main source of endogenous RAGE, we
analyzed lung samples of mice treated with the PACAP-38 peptide
for 3 months.
Results
The Shedding of RAGE is Inducible by Activation of
Different G Protein-coupled Receptors
For investigation whether the proteolytic machinery responsible
for the shedding of RAGE is inducible via activation of G protein-
coupled receptors, we generated cell lines co-expressing RAGE
and a respective GPCR. The PAC1 receptor, the V2 vasopressin
and the oxytocin receptor were included in the study because these
GPCRs act through different major signaling pathways. In all
three cases we found the shedding of RAGE to be inducible by
agonist-induced GPCR activation (Figure 1). In culture superna-
tant of cells challenged with respective agonist the amount of
soluble RAGE was significantly increased. Whereas arginine
vasopressin (AVP) treatment doubled the amount of sRAGE,
PACAP and oxytocin (OT) treatment induced the shedding of
RAGE 4 to 5-fold. The doublet band of sRAGE in the
supernatant of PAC1/RAGE cells represents glycosylated and,
with lower molecular weight, unglycosylated soluble RAGE [16].
Due to lower RAGE expression, only glycosylated RAGE is
shedded from the other cell lines. The amount of full-length
RAGE in cell lysates was unaltered following shedding induction
(Figure 1A). For identification of the signaling pathways involved
in GPCR-induced RAGE shedding we focused on the PAC1
receptor because this receptor uses a multi-branched signaling
network which also covers the signaling routes usually used by the
V2R and OTR. While the PAC1 receptor is known to be coupled
to adenylyl cyclase, phospholipase Cb, calcium signaling and MAP
kinases, the OTR is mainly linked to phospholipase Cb and
calcium signaling and the V2R to adenylyl cyclase.
Since ectodomain shedding is taking place at the cell surface, we
quantified the amount of RAGE at that cellular compartment. For
this purpose, cell surface proteins were labeled with a membrane-
impermeable biotinylation reagent and after that shedding was
induced for 2 hours with PACAP-27. Biotinylated proteins in cell
culture supernatants and intact cells were isolated separately.
Biotinylated secreted and full-length RAGE variants were
quantified by Western blot analysis. In these experiments,
PACAP-27 treatment increased the amount of secreted RAGE
in the cell culture supernatant two-fold (Figure 2A) and
significantly decreased the amount of plasma membrane-located
full-length RAGE by 30% (Figure 2B). This experiment demon-
strates that soluble RAGE is not released from intracellular pools
by exocytosis, instead it is generated by proteolytic cleavage of full-
length RAGE at the cell surface.
The Shedding of RAGE is Inducible by Activation of the G
Protein-coupled PAC1 Receptor in a Dose-dependent
Manner
The PAC1 receptor is able to bind different PACAP ligands
with similar high affinity. Treatment of PAC1/RAGE cells with
300 nM of either PACAP-27, PACAP-38 or acetylated PACAP-
38 resulted in a strong and comparable induction of RAGE
shedding (Figure 3A). In addition to natural PACAP peptides,
acetylated PACAP-38 was used due to its increased stability
against aminopeptidases. However, this did not influence the
potency of shedding induction. The ligand VIP (Vasoactive
Intestinal Peptide), which has a thousand-fold lower binding
affinity for the PAC1 receptor than PACAP peptides (KD 500 nM
vs. 0.5 nM) [25], [26] was not able to induce the shedding of
RAGE. To demonstrate further that the PAC1 receptor is
required for the PACAP-induced stimulation of shedding, we also
analyzed the effect of PACAP on HEK cells expressing only
RAGE but not the PAC1 receptor. In these cells PACAP-27 was
not able to induce the shedding of RAGE (Figure 3B). To validate
that the shedding machinery is intact in these cells, the cells were
also treated with the well-known shedding inducer PMA.
Treatment with PMA (1 mM for 4 h) caused a 4-fold increase in
the amount of sRAGE (Figure 3B). The phorbol ester PMA is
a protein kinase C activator and a well-known shedding inducer
[27] which activates RAGE shedding via calcium-dependent PKC
isoforms PKCa and PKCbI [16].
Same experiments were performed on HEK/RAGE cells
lacking OTR and V2R expression. On these cells, neither OT
nor AVP were able to induce the release of RAGE (data not
shown). Thus agonist-induction shedding of RAGE strictly
requires the presence of respective GPCR.
Next we analyzed whether the shedding of RAGE in PAC1/
RAGE cells is dependent on the PACAP concentration. Cells were
treated with different PACAP-27 hormone concentrations up to
3 mM for 4 h, and then the amount of shedded RAGE was
determined by Western blot analysis (Figure 4). PACAP-27
induced the shedding of RAGE in a dose-dependent and saturable
manner. 300 nM PACAP-27 caused a 2.5 fold increase of soluble
RAGE (sRAGE) and a 4-fold increase was detected after
application of 1 mM and 3 mM PACAP-27 (Figure 4). In cell
lysates, the amount of full-length RAGE (RAGE fl) was unaltered.
Thus, increased amounts of sRAGE are not caused by increased
RAGE expression.
To analyze the kinetic of PACAP-induced RAGE shedding, we
investigated shedding over a time period of six hours. Detectable
amounts of sRAGE were noticed after 30 min of stimulation, and
the amount of sRAGE continuously increased during the first
three hours of 300 nM PACAP-27 treatment (Figure 5A). Longer
lasting stimulation increased the amount of sRAGE only
marginally and had no effect on the expression of full-length
RAGE (RAGE fl). Prior to incubation with PACAP-27, cells were
pre-treated with the protein biosynthesis inhibitor cycloheximide
to ensure that an enhanced amount of RAGE cannot be caused by
de novo gene expression.
To estimate the potency of PACAP-induced RAGE shedding in
our cellular system, the observed effects were compared to effects
of phorbol ester-mediated RAGE shedding.
GPCR Activation Induces Shedding of RAGE
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Time-dependent treatment of PAC1/RAGE cells with PMA
(1 mM) resulted in an increased shedding of RAGE. The kinetic of
PMA-induced RAGE shedding was comparable with the PACAP-
induced kinetic (Figure 5A vs. Figure 5B).
In a previous study we demonstrated that zinc-dependent
metalloproteinases ADAM10 and MMP9 (Matrix-Metalloprotei-
nase 9) conduct RAGE shedding [16]. Therefore, we analyzed
whether PACAP-induced shedding is also mediated by metallo-
proteinases. Treatment of PAC1/RAGE cells with the broad
spectrum metalloproteinase inhibitor GM6001 (20 mM) strongly
reduced PACAP-27-mediated RAGE shedding (Figure 6). To
investigate the contribution of ADAM10 and MMP9 in PACAP-
Figure 1. Stimulation of RAGE shedding via ligand-induced activation of different G protein-coupled receptors in HEK cells. The cell
line co-expressing RAGE and the PAC1 receptor (PAC1/RAGE) was stimulated with PACAP-27, cells co-expressing RAGE and the V2 vasopressin
receptor (V2R/RAGE) were treated with arginine-vasopressin (AVP) and cells co-expressing RAGE and the oxytocin receptor (OTR/RAGE) were
stimulated with oxytocin (OT). As control, cell lines were mock-stimulated with comparable volumes of water. After stimulation with 300 nM of each
hormone for 4 h the cell culture supernatant was collected and the proteins were precipitated. Secreted RAGE (sRAGE) was detected by Western
blotting using the polyclonal antibody 3260, followed by an anti-rabbit antibody labeled with horseradish peroxidase and ECL. Full-length RAGE and
actin were detected in cell lysates by Western blot analysis. For quantification the experiments were done in triplicates. (A) Western Blots for secreted
RAGE (sRAGE) in cell culture supernatants, full-length RAGE (RAGE fl) and Actin in cell lysates. (B) Quantitative analysis: Shown are the mean effects 6
S.D., significance was determined by the One-way ANOVA Bonferroni test (* = P,0.05; ** = 0.01; *** = P,0.001).
doi:10.1371/journal.pone.0041823.g001
Figure 2. Induction of RAGE shedding at the cell surface with PACAP-27. Cell-surface proteins of full-length RAGE and PAC1 coexpressing
cells (PAC1/RAGE cells) were biotinylated using a membrane-impermeable biotinylation reagent. PACAP-27 and control treatment was then
performed for 2 h. The amount of secreted biotinylated (A) and cell-anchored biotinylated RAGE (B) was determined separately under constitutive or
PACAP-stimulated conditions after isolation of biotinylated proteins. RAGE was detected by Western blotting using antibody Mab5328 and ECL;
typical blots are shown. Left image, amount of secreted biotinylated RAGE; right images, cell surface-located biotinylated RAGE and actin in total cell
lysates. For quantification the experiments were performed in triplicates. Shown are the mean effects 6 S.D., significance was determined by the
One-way ANOVA Bonferroni test (* = P,0.05; ** = P,0.01).
doi:10.1371/journal.pone.0041823.g002
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induced RAGE shedding we used the ADAM10/MMP9 selective
inhibitor GI254023X. In in vitro assays with recombinant
proteinases, the IC50 values for ADAM10 and MMP9 are 5.3
and 2.5 nM, respectively [28]. In cellular assays, even in a high
micromolar concentration (30 mM), GI254023X did only mar-
ginally inhibit PMA-induced shedding processes [28], [29].
GI254023X applied in 25 mM concentration strongly inhibited
constitutive (72% inhibition) as well as the PACAP-induced
shedding (86% inhibition) of RAGE (Figure 7A). At a concentra-
tion of 1 mM constitutive shedding of RAGE was reduced about
67% and PACAP-induced shedding about 75% (Figure 7B). Even
at a concentration of 100 nM (Figure 7C), GI254023X slightly
inhibited the shedding of RAGE, suggesting that ADAM10 and/
or MMP9 are playing important roles in PACAP-induced RAGE
shedding. Just like the biotinylation experiment, the data obtained
with metalloproteinase inhibitors clearly demonstrate that shed-
ding and not exocytosis is responsible for the generation of soluble
RAGE.
To confirm that ADAM10 and MMP9 act as sheddases on
RAGE, we additionally performed siRNA-mediated knock-down
experiments. Here we investigated the contribution of ADAMs 10
and 17 as well as of MMPs 2 and 9. Whereas the knock-down of
ADAM10 and MMP9 resulted in a , 50% reduction of
constitutive RAGE shedding, the release of soluble RAGE was
only slightly influenced after the knock-down of ADAM17 and not
at all after knock-down of MMP2 (Figure 8). PACAP-induced
RAGE shedding was mostly reduced after knock-down of
ADAM10 and MMP9 expression. However, decreased PACAP-
induced RAGE proteolysis was also evident after reducing
ADAM17 expression. In all cases siRNA-mediated knock-downs
Figure 3. Stimulation of RAGE shedding with different PACAP peptides in PAC1/RAGE cells. (A) PAC1/RAGE cells were incubated for 4 h
with either 300 nM acetylated PACAP-38, PACAP-38, PACAP-27 or VIP; H2O: mock-treated cells (negative control). Then sRAGE was detected and
quantified by Western blotting as described in Figure 1. Shown are the mean effects 6 S.D., significance was determined by the One-way ANOVA
Bonferroni test (ns = P.0.05; *** = P,0.001). (B) RAGE expressing cells were incubated for 4 h with PMA (1 mM), PACAP-27 (300 nM) or DMSO as
control. Detection and quantification of secreted RAGE as well as significance was determined as described in figure part A; (ns = P.0.05; ** =
P,0.01).
doi:10.1371/journal.pone.0041823.g003
Figure 4. PACAP-induced dose-dependent shedding of RAGE. PAC1/RAGE cells were treated for 4 h with increasing PACAP-27
concentrations (ranging from 10 nM up to 3000 nM). Afterwards the medium was collected and sRAGE was identified with the Ab3260 as described
in Figure 1. For quantification, the experiments were done in triplicates. Shown are the mean effects6 S.D. Full-length RAGE and actin were detected
in total cell lysates by Western blot analysis.
doi:10.1371/journal.pone.0041823.g004
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did not prevent expression of the target protein completely and
due to variations in knock-down efficiencies a comparative analysis
of the contribution of metalloproteinases is impossible. Neverthe-
less, the result of our siRNA-mediated knock-down experiments
reinforce our previous interpretation that ADAM10 and MMP9
are important players in PACAP-induced RAGE shedding. In
addition, the new experiments demonstrate an involvement of
ADAM17 in PACAP-induced RAGE shedding and exclude the
contribution of MMP2.
Analysis of the Signaling Pathways Involved in PACAP-
induced RAGE Shedding
Binding of a PACAP agonist to the PAC1 receptor leads to
activation of several intracellular signaling cascades including the
adenylate cyclase system, stimulation of phospholipase C and the
MAP kinase pathway [23]. Our next aim was to elucidate the
signaling pathway(s) involved in PACAP-induced RAGE shed-
ding.
As the name PACAP implies, it activates the adenylate cyclase/
protein kinase A (PKA) pathway. Therefore the effects of H89
(5 mM), a cell-permeable inhibitor of PKA, and KT5720 (1 mM),
a more specific cell-permeable inhibitor of PKA, on the
stimulation of RAGE shedding were tested. Both inhibitors had
no effect on the PACAP-induced shedding of RAGE (Figure 9A,
B).
We also analyzed the effect of direct adenylate cyclase/PKA
activation on RAGE shedding. For this purpose RAGE expressing
cells were treated with either Forskolin (50 mM), an activator of the
adenylate cylcase, or 8-Bromoadenosine 39, 59-cyclic monopho-
sphate (8-Br-cAMP, 1 mM), an activator of PKA. Both compounds
Figure 5. Time dependence of RAGE shedding induced by either PACAP (A) or PMA (B). Upper figure part: representative Western blots
for detection of sRAGE, full-length RAGE (RAGE fl) and actin; middle figure part: Quantitative analysis of sRAGE amounts; lower figure part:
Quantification of full-length RAGE expression. PAC1/RAGE cells were incubated for different periods of time (15 min up to 360 min) using either
300 nM PACAP-27 or 1 mM PMA. sRAGE was detected and quantified as described in Figure 1. Full-length RAGE and actin were analyzed in cell lysates
by Western blotting using either the monoclonal anti-RAGE antibody 5328 or anti-actin antibody A2066. Detection was performed with ECL. For
quantification of sRAGE and full-length RAGE, the experiments were done in triplicates. Shown are the mean effects 6 S.D.
doi:10.1371/journal.pone.0041823.g005
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did not activate the shedding of RAGE (Figure 9C) supporting the
assumption that the adenylate cylase/PKA signaling cascade does
not contribute to the regulated proteolysis of RAGE. As control,
the biological activity of Forskolin was validated using the
GloSensor cAMP assay (Promega), data not shown.
PAC1 receptor activation also leads to stimulation of phospho-
lipase C (PLC) which produces the second messenger molecules
DAG and IP3 (Inositol trisphosphate) [23]. Afterwards calcium is
released from intracellular stores leading to activation of protein
kinase C (PKC).
Figure 6. Effect of metalloproteinase inhibitor GM6001 on PACAP-induced RAGE shedding. PAC1/RAGE cells were pre-treated for 1 h
with either 20 mM GM6001 or solvent, then 300 nM PACAP-27 was added for 2 h; DMSO: mock-treated cells (negative control). Secreted RAGE was
detected and quantified as described in Figure 1. Full-length RAGE and actin were detected in total cell lysates by Western blot analysis. Shown are
the mean effects 6 S.D., significance was determined by the One-way ANOVA Bonferroni test (ns = P.0.05; ** = P,0.01). Full-length RAGE and
actin were detected in total cell lysates by Western blot analysis.
doi:10.1371/journal.pone.0041823.g006
Figure 7. Effect of metalloproteinase inhibitor GI254023X on PACAP-induced RAGE shedding. PAC1/RAGE cells were pre-treated for 1 h
with either 25 mM (A), 1 mM (B) or 100 nM (C) GI254023X or solvent (DMSO), then 300 nM PACAP-27 was added for 2 h; DMSO: mock-treated cells
(negative control). Soluble RAGE was detected and quantified as described in Figure 1. Full-length RAGE and actin were detected in total cell lysates
by Western blot analysis. Shown are the mean effects 6 S.D., significance was determined by the One-way ANOVA Bonferroni test (ns = P.0.05; ***
= P,0.001).
doi:10.1371/journal.pone.0041823.g007
GPCR Activation Induces Shedding of RAGE
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For analysis of PACAP-induced activation of different PKC
isoenzymes, two different PKC inhibitors were applied: Go¨6976
selectively inhibits calcium-dependent PKC isoforms (PKCa,
PKCbI); Go¨6983 selectively inhibits the PKC isozymes PKCa,
PKCb, PKCc, PKCd and PKCf but it does not block PKCm
(IC50 = 20 mM). Both PKC inhibitors reduced the PACAP-
induced shedding of RAGE: Treatment with Go¨6976 and
Go¨6983 (both 1 mM) resulted in an approximate 60% and 50%
inhibition of PACAP-stimulated RAGE shedding (Figure 10A).
For further analysis of the contribution of Ca2+ in the shedding of
RAGE, the PAC1/RAGE cells were pre-treated with the IP3
receptor antagonist 2-APB (75 mM) and then the shedding process
was induced for 2 h with PACAP-27. Compared to mock-treated
cells, 2-APB decreased the PACAP-induced release of soluble
RAGE about 40% (Figure 10B).
Besides PKC, Ca2+ also activates calmodulin dependent protein
kinase II (CaMKII) and PACAP-initiated stimulation of CaMKII
has been described [30]. Treatment of PAC1/RAGE cells with
CK59 (20 mM), a cell-permeable CaMKII inhibitor
(IC50,10 mM), decreased the PACAP-induced shedding of
RAGE about 43% (Figure 10C). These results demonstrate that
Ca2+ signaling, PKCa/PKCbI and CaMKII play substantial roles
in the activation of metalloproteinase-mediated RAGE shedding.
Since Ca2+ appears to be a dominant regulator of induced
RAGE shedding, we analyzed whether agonistic activation of our
cell lines leads to elevated intracellular Ca2+ levels. Depending on
the coexpressed GPCR, RAGE expressing cells were treated with
either PACAP-27, AVP or OT (each 300 nM). In all RAGE/
GPCR coexpressing cells agonist treatment induced a strong
intracellular Ca2+ signal as measured via calcium sensor Fura-2-
AM (Figure 11). In HEK cells neither hormone induced calcium
signaling. Thus activation of GPCRs is required for elevation of
intracellular calcium levels. The finding that also activation of the
V2 receptor can modulate intracellular calcium is an explanation
for its involvement in induced RAGE shedding, because by using
PKA inhibitor KT5720 we could exclude an involvement of
cAMP/PKA signaling in V2R-induced RAGE shedding (data not
shown).
Since PACAP is also able to activate the phosphatidylinositol 3-
kinase (PI3-kinase) [31] and mitogen-activated protein kinases
(MAP kinases) [32], [33], we also investigated whether these
signaling pathways contribute to the PACAP-induced shedding of
RAGE. Treatment of PAC1/RAGE cells with 50 mM LY294002
(a specific, cell-permeable inhibitor of PI3-kinase) decreased
PACAP-induced shedding of RAGE about 50% (Figure 12).
The use of PD98059 (50 mM), which is a selective, reversible and
cell-permeable inhibitor of MAP kinases MEK1 and MEK2,
decreased PACAP-induced shedding of RAGE about 34%
(Figure 13).
By using various inhibitors we identified several signaling
pathways contributing to RAGE shedding. Next we analyzed
whether these signaling pathways are contributing in parallel to
the shedding of RAGE. Combinatorial treatment of cells with
MAP kinase inhibitor and either PKC or CamKII inhibitor did
not result in an enhanced inhibition of PACAP-induced RAGE
shedding (Figure 14). When compared to the presence of only
one inhibitor, parallel inhibition of PI3 kinase and PKC resulted
in reduced shedding of RAGE. The latter result suggests that
activation of metalloproteinase-mediated RAGE shedding via
PI3K and PKC is mediated by signaling pathways acting in
parallel. CamKII and PKC appear to rather contribute to
cascade-like signaling which also involves MAP kinases
(Figure 15).
Figure 8. Effects of RNAi-mediated knock-down on the shedding of RAGE. PAC1/RAGE cells were transfected with stealth RNAi
oligonucleotide duplexes (Invitrogen) targeting either ADAM10 (AD10), ADAM17 (AD17), MMP9 or MMP2. As control (-) cells were transfected with
a stealth RNAi control oligonucleotide duplex (Invitrogen). Experiments were performed 48 h after transfection. Secretion of RAGE was analyzed
under unstimulated (H2O, n = 10) and PACAP-induced (300 nM, n= 5) conditions for 3 h. (A) Typical Western blots and gelatin zymography are
shown, (B) Quantitative analysis of secreted RAGE. RAGE secreted into the cell culture supernatant and full-length RAGE in cell lysates were detected
with antibody Mab5328. The enzymatic activity of MMP9 and MMP2 in cell culture supernatants was determined by gelatin zymography as described
in Materials and Methods. In cell lysates full-length RAGE (fl-RAGE), ADAM10 (pro and mature (m) forms), and ADAM17 (pro and mature (m) forms)
were detected with suitable antibodies (see ‘‘Materials and Methods’’). As a loading control actin was detected in cell lysates by Western blotting.
Shown in the quantitative analysis (B) are the mean effects6 S.D., significance was determined by the One-way ANOVA Bonferroni test (ns = P.0.05;
* = P,0.05; ** = P,0.01; *** = P,0.001).
doi:10.1371/journal.pone.0041823.g008
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Analysis of RAGE Shedding in Mouse Lungs
Finally we were interested whether PACAP-stimulated shedding
is also evident in vivo. For this purpose, mice were treated for 3
months intranasally with either PACAP-38 or mock administra-
tion solution [24]. Since highest amounts of RAGE are found in
the lung and PACAP receptors are also present in this organ,
mouse lungs were isolated and fractionated into portions contain-
ing either soluble lung proteins or membrane proteins. In the
fraction of soluble lung proteins the amount of sRAGE was
increased by about 60% in PACAP-treated mice (Figure 16). The
amount of membrane-bound full-length RAGE was not altered by
PACAP-treatment (Figure 16).
Discussion
In this report we provide evidence that metalloproteinase-
mediated shedding of the type I membrane protein RAGE is
inducible by activation of G protein-coupled receptors which are
expected to be linked to different main signal transduction
pathways. We demonstrate that RAGE shedding can be induced
via activation of the V2 vasopressin, the oxytocin and the PAC1
receptor. The shedding of RAGE was induced 2 to 5-fold after
activation of examined GPCR. Observed differences provide no
information about the efficiency of individual GPCR-activated
shedding induction, because cell lines expressing different amounts
of GPCR and RAGE were compared. Nevertheless, our results
Figure 9. Analysis of adenylate cyclase/protein kinase A (PKA) signaling on the PACAP-induced RAGE secretion. (A) and (B), effect of
protein kinase A inhibition; (C) effect of adenylate cyclase/protein kinase A activation. (A) and (B), PAC1/RAGE cells were pre-treated for 1 h with
either PKA inhibitor H89 (5 mM, figure part A) or KT5720 (1 mM, figure part B) then 300 nM PACAP-27 was added for 2 h. The effects of PKA inhibitors
were also analyzed in the absence of PACAP stimulation. Secreted RAGE was detected and quantified as described in Figure 1. Shown are the mean
effects 6 S.D., significance was determined by the One-way ANOVA (ns = P.0.05). For quantification the experiments were performed in triplicates.
(C) Cells were incubated with either adenylate cyclase stimulator Forskolin (50 mM) or PKA activator 8-Br-cAMP (1 mM) for 2 h. Secreted RAGE in the
cell culture supernatant was detected and quantified by Western Blot as described above. H2O, DMSO: mock-treated cells (negative controls).
doi:10.1371/journal.pone.0041823.g009
Figure 10. Effect of Ca2+ on the shedding of RAGE. PAC1/RAGE cells were pre-incubated for 1 h with respective inhibitor and then 300 nM
PACAP-27 was added for 2 h. Secreted RAGE in the cell culture supernatant was detected and quantified as described in Figure 1. Shown are the
mean effects6 S.D., significance was determined by the One-way ANOVA test (ns = P.0.05; ** = P,0.01; *** = P,0.001). (A) Effect of protein kinase
C inhibitors Go¨6976 and Go¨6983 (both 1 mM); (B) effect of the IP3 receptor modulator 2-APB (75 mM), and (C) effect of the calcium/calmodulin-
dependent protein kinase II inhibitor CK59 (20 mM). In all experiments effects of inhibitors were also analyzed in the absence of PACAP stimulation.
doi:10.1371/journal.pone.0041823.g010
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clearly demonstrate that the RAGE shedding machinery is
inducible via activation of various GPCRs. For the detailed
analysis of involved signaling pathways we focused on the multi-
branched signaling network of the PAC1 receptor since this also
covers the more restricted signaling routes of V2R and OTR.
By a biotinylation experiment, we demonstrated that PACAP-
induced RAGE shedding takes place at the cell surface where
a substantial amount of plasma membrane-located RAGE is
proteolytically cleaved after activation of PAC1 receptors. Similar
results have been published for PMA-induced RAGE shedding
[16]. A detailed analysis for the PAC1 receptor demonstrated that
Ca2+ signaling, PKCa/PKCbI, CaMKII, PI3 kinase and MAP
kinases are involved in the shedding activation process. A
contribution of adenylate cyclase/PKA signaling in PACAP-
induced RAGE proteolysis was not evident in our cellular system.
In V2R/RAGE cells we could also not detect an involvement of
adenylate cyclase/PKA signaling in AVP-induced RAGE shed-
ding. In all our cell lines expressing different GPCRs (PAC1/
RAGE, V2R/RAGE and OTR/RAGE) we observed agonist-
induced intracellular calcium signaling. Therefore we conclude
Figure 11. Measurement of intracellular calcium signaling. PAC1/RAGE (A), V2R/RAGE and OTR/RAGE cells (B) as well as HEK cells (A/B) were
incubated for 30 min with 1,5 mM fura 2-AM. Then the cells were suspended and collected by centrifugation (0.4 g), after suspending cells in calcium
buffer, measurements were performed with a spectrofluorometer. The respective agonists were applied to the cells after 100 s. As a negative control,
either PACAP-27 or OT and AVP were added to HEK cells. Rising intracellular Ca2+ levels are detected by an increase in the fluorescence ratio 340 nm/
380 nm.
doi:10.1371/journal.pone.0041823.g011
Figure 12. Role of phosphatidylinositol 3-kinase in PACAP-induced RAGE shedding. PAC1/RAGE cells were pre-incubated for 1 h with
PI3K inhibitor LY294002 (50 mM) and then 300 nM PACAP-27 was added for 2 h; DMSO: mock-treated cells (negative control). Secreted RAGE in the
cell culture supernatant was detected and quantified as described in Figure 1. Shown are the mean effects6 S.D., significance was determined by the
Student’s unpaired t test (*** = P,0.001).
doi:10.1371/journal.pone.0041823.g012
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that Ca2+ seems to be an important regulator of the RAGE
shedding machinery.
Analysis of lungs isolated from PACAP-treated mice further
showed that the shedding of RAGE is also inducible in vivo. So far
induced shedding of RAGE was demonstrated only for unphysio-
logical stimulators such as the phorbolester PMA and the calcium
ionophore A23187 [16].
In connection with the development of Alzheimers disease it is
important to consider that at least two aspects of metalloprotei-
nase-mediated shedding processes are essential: (i) cleavage of APP
by ADAM10 prevents generation of neurotoxic Ab peptides; (ii)
cleavage of full-length RAGE by ADAM10 prevents binding of the
RAGE ligand Ab to cell-bound RAGE [34]. Cell-bound RAGE is
known being an Ab transporter importing Ab from the blood into
the brain and also being a neuronal receptor mediating neurotoxic
effects of Ab. Thus activation of ADAM10-mediated cleavage of
RAGE and APP should counteract the development of AD, and
furthermore stimulation of RAGE shedding should prevent at least
some pro-inflammatory effects associated with diabetes mellitus.
The therapeutic potential of PACAP in the treatment of AD was
investigated by us in an AD mouse model. Intranasal application
of PACAP-38 increased a-secretase-mediated APP processing,
induced expression of various neuroprotective genes and improved
memory in mice [24]. In the same study, we detected a strong
reduction of the RAGE mRNA level in the brain of PACAP-
treated mice. It is known that RAGE expression is induced by an
autocrine mechanism of ligand binding and RAGE signaling [7].
This activation loop can be disrupted by the shedding of
membrane-bound signaling capable RAGE and/or by decreasing
the amount of RAGE ligands such as Ab. In our mouse model
both options are likewise possible. This finding and our current
data demonstrate that shedding of at least APP and RAGE is
inducible by administration of PACAP in vivo. Thus, application of
PACAP may also have therapeutic potential for the treatment of
AD or inflammatory diabetic conditions in humans.
In cells coexpressing RAGE and the PAC1 receptor, the
shedding of RAGE was inducible by various PAC1 receptor
agonists. Induction of RAGE shedding was dose-dependent and
saturable. A similar effect has been observed for PACAP-induced
shedding of APP [19] suggesting activation of the same shedding-
machinery. The broad spectrum metalloproteinase inhibitor
GM6001 was able to prevent the PACAP-induced shedding of
RAGE. ADAM10 and ADAM17 are the main sheddases re-
sponsible for ectodomain shedding of a number of cell surface
proteins. However, in a previous study we found ADAM10 and
MMP9 to mediate RAGE shedding [16]. The contribution of
these proteinases in PACAP-induced RAGE shedding was
analyzed in more detail by using the ADAM10/MMP9-selective
inhibitor GI254023X. In our cellular assay 25 mM and even
a concentration of 1 mMGI254023X strongly reduced constitutive
RAGE shedding; also PACAP-induced shedding of RAGE was
significantly reduced. At a concentration of 100 nM, a slight
inhibition of RAGE shedding was still observed. In in vitro assays
with recombinant proteinases, GI254023X discriminates between
ADAM17 (IC50 = 541 nM) and ADAM10 (IC50 = 5.3 nM)/
MMP9 (IC50 = 2.5 nM) [28]. However, in cellular assays, IC50
values appear to be much higher: at 30 mM GI254023X has been
reported to reduced PMA-induced shedding by only 20% [28],
[29]. In the case of ADAM10-mediated CD23 shedding, 1 mM of
GI254023X was sufficient to block about 75% of CD23 release
[35]. Thus, our observation that the constitutive as well as the
PACAP-induced shedding of RAGE was inhibited with 1 mM
GI254023X about 67% and 75% strongly argues for a contribu-
tion of ADAM10 in that process. By applying siRNA-mediated
knock-down experiments we could confirm the role of ADAM10
and MMP9 in constitutive and PACAP-induced RAGE shedding
and in addition a contribution of ADAM17 in PACAP-induced
RAGE shedding was observed. According to our experimental
setting, we cannot exclude the contribution of other proteinases in
RAGE shedding. However, the involvement of ADAM10 in
constitutive RAGE shedding is supported by findings of other
Figure 13. Role of the MEK1 MAP kinase pathway in PACAP-induced RAGE shedding. PAC1/RAGE cells were pre-incubated for 1 h with
MEK1 Inhibitor PD98059 (50 mM) and then 300 nM PACAP-27 was added for 2 h. Secreted RAGE was detected and quantified as described in Figure 1.
Shown are the mean effects 6 S.D., significance was determined by the One-way ANOVA test (ns = P.0.05; ** = P,0.01).
doi:10.1371/journal.pone.0041823.g013
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research groups where either experiments with genetically
modified mouse embryonic fibroblasts or an ADAM10 over-
expression strategy were utilized [14], [15].
Our comparative analysis of PACAP-induced RAGE shedding
versus phorbol ester-induced shedding revealed a similar kinetic in
the examined cellular system. Shedding increased continuously
during the first three hours after its induction and reached
a maximum after about four hours. Similar results for PMA-
induced shedding have been described [36]. The potency of
GPCR-mediated cellular activation and hence the induction of
ectodomain shedding depends on the GPCR density on the cell
surface and on the agonist concentration. Our finding that
intranasal application of PACAP to mice is sufficient for induction
of RAGE shedding in the mouse lung demonstrates that an
increased shedding of RAGE is achievable by activation of
endogenously present PACAP receptors. Large amounts of full-
length RAGE are expressed in the lung [1]. Therefore the lung
can possibly serve as a pool for the release of soluble RAGE into
the blood stream upon shedding induction. As already mentioned,
soluble RAGE prevents proinflammatory full-length RAGE
signaling.
The name PACAP (Pituitary adenylate cyclase-activating polypeptide)
implies adenylate cyclase and subsequently protein kinase A (PKA)
as targets of PACAP receptor activation. However, in our study we
did not observe any effects of either adenylate cyclase/PKA
activation or inhibition on the shedding of RAGE. PACAP-
induced APP processing was also identified to occur independently
from the adenylate cyclase/PKA system [19]. ADAM-mediated
shedding processes seem to be largely independent from adenylate
cyclase/PKA signaling. Instead, calcium signaling is playing an
important role. Our finding that AVP-induced activation of the
vasopressin V2 receptor also induced RAGE shedding indepen-
dent from adenylate cyclase/PKA signaling, can be explained by
the fact that besides activation of adenylate cyclase/PKA
signaling, intracellular calcium levels are also increased upon V2
receptor activation [37]. We observed a reduction of PACAP-
induced RAGE shedding after treatment of cells with various
inhibitors interfering with Ca2+ signaling. Inhibition of intracel-
Figure 14. Influence of simultaneously added kinase inhibitors on the shedding of RAGE. PAC1/RAGE cells were pre-incubated for 1 h
with (A) MEK1 inhibitor PD98059 (50 mM) and PKC inhibitor Go¨6983 (1 mM); (B) MEK1 inhibitor PD98059 (50 mM) and CaMKII inhibitor CK59 (20 mM) or
(C) PI3K inhibitor LY294002 (50 mM) and PKC inhibitor Go¨6983 (1 mM). Then 300 nM PACAP-27 was added for 2 h. Secreted RAGE was detected and
quantified as described in Figure 1. Shown are the mean effects 6 S.D., significance was determined by the One-way ANOVA test (ns = P.0.05; * =
P,0.05).
doi:10.1371/journal.pone.0041823.g014
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lular calcium release as well as blockade of calcium-dependent
PKC isoforms or calcium/calmodulin-dependent protein kinase II
(CaMKII) significantly reduced the PACAP-induced RAGE
shedding. The importance of Ca2+ signaling in the induction of
RAGE shedding is supported by our finding that activation of the
oxytocin receptor leads to elevated sRAGE levels; this receptor is
known to be connected to Ca2+ signaling [22].
A role for the phosphatidylinositol 3-kinase (PI3-kinase)
pathway has been demonstrated for the anti-apoptotic effect of
PACAP [31]. Therefore, we analyzed whether PI3-kinase is also
involved in PACAP-mediated RAGE proteolysis. Inhibition of
PI3-kinase using LY294002 strongly reduced the PACAP-induced
RAGE shedding. We also identified MAP kinase signaling to
contribute to PACAP-induced RAGE shedding. MAP kinases play
important roles in the signal transduction of receptor tyrosine
kinases (RTKs) such as the insulin receptor. Moreover, insulin
signaling has been demonstrated to induce ADAM10-mediated
shedding of Klotho [38]. Therefore, it is likely that also the
ADAM10-mediated cleavage of APP and RAGE is inducible via
activation of insulin receptors; for APP processing this has already
been demonstrated [39], [40].
Given that increased Ca2+ levels are sufficient for induction of
ADAM-mediated shedding processes, the activation of RAGE
ectodomain shedding should be achievable via stimulation of
different receptor classes including GPCRs, RTKs and ligand-
controlled Ca2+ channels.
It is well documented that shedding processes can be induced by
quite distinct stimuli. For example, the catalytic activity of
ADAM17, but not that of ADAM10, can rapidly and reversibly
be induced by signaling pathways stimulated by thrombin, EGF,
lysophosphatidic acid and TNFa. Activation of ADAM17 was
independent from its cytoplasmic tail but required the presence of
the transmembrane domain and led to the exposure of the
ADAM17 catalytic site [41]. It is elusive how these observations
are linked on the molecular level, but they rather argue against
a direct inside-out signaling mechanism. On the other hand, the
C-terminus of ADAM10 is required for the induction of ADAM10
activity by calcium [42] and a putative PKC phosphorylation site
and SH3 domains in the ADAM10 C-terminus are possibly
involved in shedding activation [43]. Collectively viewed, the
molecular mechanisms linking GPCR activation and protein
ectodomain shedding appear to be multilayered and they also
seem to be different for specific proteinases.
Independent from the missing links of cell and sheddase
activation, our presented data provide evidence that pharmaco-
logical stimulation of RAGE shedding may open alternative
treatment strategies for AD or RAGE-mediated diabetic compli-
cations in the future.
Figure 15. Model of the intracellular pathways involved in PACAP-induced RAGE shedding. In this study we demonstrated an
involvement of MAP kinase, PI3-kinase, PKC and CaMKII in PAC1 receptor-induced activation of metalloproteinase-mediated RAGE shedding.
Molecular mechanisms linking signaling cascades with metalloproteinase activation are still unknown (dotted lines). CaMKII: calmodulin-dependent
protein kinase II; DAG: diacylglycerol; IP3: inositol 1,4,5-triphosphate; MAP kinase: mitogen-activated protein kinase; PI3-kinase: phosphatidylinositol
3-kinase.
doi:10.1371/journal.pone.0041823.g015
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Materials and Methods
Antibodies and Reagents
The following antibodies were used: anti human RAGE N-
terminal antibody Mab5328 (Millipore) detecting membrane-
bound RAGE and rabbit serum Ab3260 detecting secreted RAGE
[16]. For detection of RAGE in mouse samples, the antibody
MAB1179 from R&D Systems was used. This antibody recognizes
the extracellular domain of murine RAGE. The anti-actin
antibody (A2066) was from Sigma-Aldrich. Anti ADAM10
(AB19026) and ADAM17 (AB19027) antibodies directed against
cytosolic ADAM domains were from Millipore.
Secondary anti-rabbit and anti-mouse peroxidase-coupled anti-
bodies and the ECL detection reagent were from Pierce (Rockford,
USA). The anti-rat POD-coupled secondary antibody was from
Merck (Darmstadt). All peptide hormones were from Bachem. All
other chemicals were either from Merck Biosciences or Sigma-
Aldrich.
Expression Vectors
RAGE: The untagged wild-type human RAGE expression
vector pcDNA6-RAGE was generated by using the human RAGE
cDNA, including its own translation termination codon. The
human RAGE cDNA was subcloned from clone IRAL-
p962E1737Q2 into EcoRI/XbaI sites of pcDNA6/V5-HisB.
PAC1: The rat PACAP type I receptor, which has 92% amino
acid identity compared to the human receptor, was used in the
experiments. The PAC1 coding region was fused at the 59end to
a myc epitope coding sequence and was combined at the 39end to
an oligonucleotide adaptor coding for a Rho epitope in a pcDNA3
vector. Expression plasmids for the C-terminal HA-tagged bovine
V2 vasopressin and human oxytocin receptor carrying a N-
terminal c-myc and FLAG epitopes and a C-terminal GFP-tag are
described elsewhere [44], [45]. The HA-tagged bovine V2
vasopressin receptor cDNA sequence was subsequently subcloned
into plasmid pcDNA3 (Invitrogen) generating pcDNA3-V2R-HA.
Transfection of Cells
HEK Flp-InTM 293 cells (human embryonic kidney cells)
(Invitrogen) were transfected with pcDNA3-PAC1 expression
plasmid using Lipofectamine 2000 (Invitrogen) and selected via
G418 to generate a stable cell line.Thenone cell clone expressing the
PAC1 receptor was transfected with pcDNA6-RAGE expression
plasmid using Lipofectamine 2000 and selected via Blasticidin.
HEK 293 cells (ATCC) stably expressing the oxytocin receptor
(OTR) [45] were transfected with the RAGE expression vector
pcDNA6-RAGE to generate stably OTR/RAGE coexpressing
cells. A single cell clone expressing RAGE and OTR was isolated
via G418 and Blasticidin selection.
HEK 293 cells (ATCC) stably expressing the bovine vasopressin
receptor (V2R) were generated by us by transfection of HEK 293
cells using plasmid pcDNA3-V2R-HA. A V2 vasopressin receptor-
expressing cell clone was isolated by using G418 selection.
Subsequently, this cell clone was transfected with plasmid
pcDNA6-RAGE and a RAGE/V2R coexpressing cell clone was
isolated via G418 and Blasticidin selection.
Small Interference RNA Experiments
Stealth RNAi duplexes were purchased from Invitrogen, and
transfections were performed according the manufacturer’s pro-
tocol. The RAGE cleavage assay was performed 48 h after
transfection.
Figure 16. Analysis of PACAP-induced RAGE shedding in vivo. Mices (N = 6) were treated intranasally with PACAP-38 for 3 months. Afterwards
mouse lungs were dissected and membrane proteins and soluble proteins were separated following tissue homogenization by ultracentrifugation.
Secreted RAGE (sRAGE) and full-length RAGE (RAGE fl) were detected by Western blotting using an antibody directed against mouse RAGE (MAB1179)
followed by an anti-rat antibody labeled with horse radish peroxidase, as loading control actin was detected. Shown are the mean effects 6 S.D.,
significance was determined by the Student’s unpaired t test (ns = P.0.05; * = P,0.05).
doi:10.1371/journal.pone.0041823.g016
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Measurement of Intracellular Free Calcium Ion
Concentration [Ca2+]i
Cells were incubated with 1,5 mM fura 2-AM in DMEM for
30 min at 37uC. Afterwards they were detached by using PBS/
0,5 mM EDTA and centrifuged at 100 g for 5 min. Pellets were
washed and resuspended in calcium buffer (10 mM HEPES,
pH 7.4, 140 mM NaCl, 5 mM KCl, 0,5 mM MgCl2, 1,5 mM
CaCl2, 10 mM glucose). Aliquots of the suspension were added to
calcium buffer and transferred into a cuvette that was placed into
a thermostatically controlled (37uC) holder. The agonists (final
300 nM) were applied to the cells after 100 s, and the changes of
the [Ca2+]i were monitored spectrofluorimetrically (Photon
Technology Int., Birmingham (USA)).
The emission wavelength was set at 510 nm, and dual-
wavelength excitations were performed at 340 and 380 nm. The
change of the Ca2+ concentration was calculated by using the ratio
340 nm/380 nm.
RAGE Cleavage Assays and Inhibitor Treatments
Cells coexpressing RAGE and GPCRs were seeded onto poly-
L-lysine-coated 6 well plates and grown for 24 h to 80-90%
confluence. Cells were washed twice with serum-free DMEM and
then secretion medium (serum-free DMEM supplemented with
2 mM glutamine) was added. Experiments in the presence of
inhibitors were performed by preincubating cells with the inhibitor
in secretion medium for 1 h at 37uC and then PACAP hormones,
arginine-vasopressin or oxytocin were added. After the appropri-
ate incubation time, cell culture supernatants were collected
centrifuged for 10 min at 660 g and proteins were precipitated
with 10% trichloroacetic acid at 4uC. Proteins were analyzed by
Western blotting. For detection of cellular proteins, the adherent
cells on the 6 well plates were washed with PBS, then dissolved in
reducing Laemmli buffer and assayed by Western blot analysis.
For comparative and quantitative analysis, effects observed with
solvent-treated cells were used as control and were set to 100%. As
a further control, the effect of the inhibitors on RAGE shedding
was also analyzed in the absence of hormones.
Biotinylation of Cell Surface Proteins
Adherent cells were washed twice with PBS and then incubated
for protein biotinylation with PBS containing 0.1 mM Sulfo-NHS-
LC-Biotin (Pierce Biotechnology) for 30 min at room temperature.
After washing with Tris-buffered saline (pH 7.4) the cells were
incubated in secretion medium for 2 hours. The cells and
supernatants were collected separately, and the supernatants were
adjusted to 0.1% SDS. The cells were dissolved in 5% SDS, and
then SDS was diluted to 0.1% by adding PBS. Biotinylated
proteins were captured with NeutrAvidin Biotin-binding agarose
(Pierce) for 2 h at 4uC. After that, the agarose beads were washed
three times with PBS/0.1% SDS. Proteins were eluted from the
binding agarose with reducing Laemmli buffer and analyzed by
Western blotting. Actin could not be detected in isolated
biotinylated protein fractions, thus demonstrating the integrity of
the cells during the course of the experiment. As a control, actin
could be detected in the cell lysate (5% SDS fraction; see above).
Western Blotting
Proteins of the cell culture supernatant or cell lysates were
separated by 10% SDS-PAGE and blotted to nitrocellulose
membranes (GE Healthcare). Membranes were probed with the
appropriate primary and secondary antibodies and the labeled
proteins were detected by chemiluminescence using the VersaDoc
system (Bio-Rad Laboratories, Munich, Germany) and quantified
via the AIDA 4.25 software (Raytest, Straubenhardt).
Gelatin Zymography
Cells were washed twice with serum free DMEM, then serum
free DMEM was added to the cells. After 18 h of incubation at
37uC, supernatants were collected and cleared from cells by
centrifugation (6606g, 10 min). For gelatin zymography 30 ml of
serum-free cell culture supernatant was mixed with 10 ml of 46
NuPAGE LDS Sample Buffer (Invitrogen), and subsequently
proteins were separated under non-reducing conditions in 10%
SDS-polyacrylamide gels containing 0.1% gelatin. After electro-
phoresis gels were washed in 2.5% Triton X-100 at room
temperature for 1 h and then incubated for 16 h at 37uC in
reaction buffer (100 mM Tris-HCl, pH 7.5, 10 mM CaCl2).
Finally the gels were stained with Coomassie Blue. Clear areas
within the stained gel result from digestion of gelatin by the
gelatinase activity of either MMP9 or MMP2.
Treatment of Mice and Samples Preparation
Ethics Statement. All animal experiments performed com-
ply with the current German laws. Approval of animal studies by:
Landesuntersuchungsamt Rheinland-Pfalz, Dienststelle
Tierschutz, Mainzerstraße 112, 56068 Koblenz, Germany.
Approval ID: 177-07/051-17.
Treatment. Three-month-old male APP[V717I] mice were
treated with PACAP38 for additional 3 months. The peptide
solution (1 mg/ml in 0.5% chitosan glutamate and 0.5% NaCl in
water; pH 4) was prepared as described [46]. The solution of
PACAP38 was administered intranasal to APP[V717I] mice 5
days a week, for 3 months. The mice were treated with 10 mg
PACAP38 per day, 10 ml for each mouse (5 ml/nostril); 5 ml/
nostril of the inert carrier was given to the control group. Mice
were sacrificed and then removed lungs were frozen on dry ice,
and then stored at 280uC.
Samples preparation. Mouse lung samples were divided
into pieces in liquid nitrogen and ice cold homogenization buffer
(1,4 M NaCl/20 mM Tris/HCl pH 7,5 with 1 proteinase in-
hibitor tablet Complete Mini (Roche) per 10 ml) in the fourfold
volume of the lung weight was added. Samples were homogenized
in a tissue lyser (Qiagen, 30 Hz, 262 min) and the suspension was
centrifuged for 2 h (100 000 g, 4uC), then the supernatant was
transferred in a new tube. The pellets containing insoluble lung
material were resuspended in the fourfold volume of homogeni-
zation buffer with the tissue lyser (30 Hz, 262 min) and afterwards
centrifuged for 15 min (16 000 g, 4uC). Then the supernatant was
discarded and the remaining pellet was suspended in a twofold
volume of TBS (with proteinase inhibitor tablet Complete Mini)
using the tissue lyser. This suspension was used for analysis of
membrane proteins.
The protein contents of the soluble and membrane protein
fractions were determined by the Bradford method. Proteins were
analyzed by Western Blotting.
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